HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma

Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players in CAR therapy, we sought to evaluate the evolution of HLA-DR exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourbon, Estelle, Sesques, Pierre, Gossez, Morgane, Tordo, Jérémie, Ferrant, Emmanuelle, Safar, Violaine, Wallet, Florent, Aussedat, Guillaume, Maarek, Alizée, Bouafia, Fadhela, Karlin, Lionel, Ghergus, Dana, Golfier, Camille, Lequeu, Hélène, Lazareth, Anne, Schwiertz, Vérane, Viel, Sébastien, Idlhaj, Maryam, Ghesquières, Hervé, Monneret, Guillaume, Bachy, Emmanuel, Venet, Fabienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989525/
https://www.ncbi.nlm.nih.gov/pubmed/35439292
http://dx.doi.org/10.1182/bloodadvances.2021006563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989525/
https://www.ncbi.nlm.nih.gov/pubmed/35439292
http://dx.doi.org/10.1182/bloodadvances.2021006563

Ejemplares similares